Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.
We report a 16-year-old man with severe heart failure due to idiopathic pulmonary arterial hypertension (IPAH). The patient was initially treated with a combination of beraprost, a prostacyclin analog, and sarpogrelate, a serotonin receptor inhibitor. However, he was unresponsive to the treatment. We then changed the treatment to sildenafil, and his condition dramatically improved. Sildenafil has an immediate pulmonary vasodilator effect in patients already receiving vasodilators for IPAH.
Kawano
Hiroaki
H
Department of Cardiovascular Medicine, Course of Medical and Dental Science, Graduate School of Biomedical Science, Nagasaki University. hkawano@net.nagasaki-u.ac.jp
Sengyoku
Hideyori
H
Satoh
Osami
O
Urabe
Shigetoshi
S
Koide
Yuji
Y
Yano
Katsusuke
K
D000293:Adolescent; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013386:Succinates / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010879:Piperazines; D011687:Purines; D012702:Serotonin Antagonists; D013386:Succinates; D013450:Sulfones; D014665:Vasodilator Agents; C064294:sarpogrelate; C048081:beraprost; D000068677:Sildenafil Citrate; D011464:Epoprostenol